U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07664852) titled 'Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression' on June 17.
Brief Summary: Among psychiatric disorders, bipolar disorder stands out due to its alarmingly high suicide rates. This condition presents unique management challenges, especially during its depressive phase, which carries the highest risk of suicide. We will conduct an academic randomized controlled trial to evaluate a new medication for bipolar depression. We will investigate the efficacy and safety of pramipexole, a potent dopamine agonist that has demonstrated significant effectiveness in bipolar disorder in preliminary studies, showing la...